Tag
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
This prospective registry reveals a significantly increased risk of stroke or transient ischemic attack within 30 days after pulsed field ablation compared to radiofrequency ablation for atrial fibrillation, highlighting important safety co
Boston Scientific slashed its 2026 sales and EPS forecasts for the second straight quarter, citing competitive pressure in pulsed field ablation and declining standalone Watchman procedures.
This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.
The SCENA-AF trial highlights the efficacy of nanosecond pulsed field ablation (nsPFA) for treating paroxysmal atrial fibrillation, achieving an 88.49% success rate at 12 months with minimal complications and a significant shift toward loca
The first-in-human VCAS trial demonstrates that high-voltage focal pulsed field ablation (PFA) safely delivers transmural lesions in thick ventricular scar tissue, significantly reducing ventricular tachycardia burden by 98% in high-risk pa
The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while main
The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complet
The ADVANTAGE AF Phase 2 study demonstrates pulsed field ablation’s safety and efficacy for persistent atrial fibrillation, introducing continuous cardiac monitoring to better assess arrhythmia burden and outcomes over one year.
This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.
